PCMA SUPPORTS STRAIGHTFORWARD POLICY SOLUTIONS TO REDUCE DRUG COSTS

Adopting common-sense policies from PCMA’s the Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access that end the anticompetitive practices of pharmaceutical manufacturers and enhance competition in the marketplace could achieve federal savings of $59.1 billion to $118.3 billion over 10 years.

- Hold pharmaceutical manufacturers accountable for their high drug prices
- Promote generic and biosimilar competition
- Enforce antitrust laws to stop lockstep pricing
- Define patent extension strategies as anticompetitive and empower FTC to challenge them
- Discourage anticompetitive “reverse payment settlements” and “pay-for-delay” agreements
- Reserve exclusivities to true innovation for orphan drugs, reference biologics, and first-generics
- Eliminate the tax deductibility of direct-to-consumer prescription drug advertising